Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding

OBJECTIVE: Compare 30‐day mortality among patients receiving the specific reversal agent andexanet alfa versus replacement prothrombin complex concentrate (PCC) in the management of direct‐acting oral anticoagulant (DOAC)–related bleeds. METHODS: Two patient‐level datasets were used: ANNEXA‐4, a pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Alexander T., Lewis, Megan, Connor, Augusta, Connolly, Stuart J., Yue, Patrick, Curnutte, John, Alikhan, Raza, MacCallum, Peter, Tan, Joachim, Green, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
General Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898077/
https://www.ncbi.nlm.nih.gov/pubmed/35280921
http://dx.doi.org/10.1002/emp2.12655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898077/
https://www.ncbi.nlm.nih.gov/pubmed/35280921
http://dx.doi.org/10.1002/emp2.12655

Ejemplares similares